Amylyx Pharmaceuticals NASDAQ: AMLX Co-Chief Executive Officer Justin Klee said the company is preparing for a key Phase 3 readout for avexitide, its lead program for post-bariatric hypoglycemia, during an appearance at the Goldman Sachs Global Healthcare Conference.
Investors need to pay close attention to PBH stock based on the movements in the options market lately.
Prestige Consumer Healthcare Inc. (PBH) Q4 2026 Earnings Call Transcript
Premium Brands has dropped into my $80–$90 buy range, presenting a compelling entry after a sharp pullback. PBH's M&A pipeline has slowed, but the Stampede acquisition adds significant U.S. capacity and growth potential, despite some near-term margin dilution. Management is shifting toward equity-funded acquisitions to protect leverage, likely resulting in higher share count but maintaining balance sheet flexibility.
Prestige Consumer Healthcare Inc. (PBH) Q3 2026 Earnings Call Transcript
Prestige Consumer Healthcare (PBH) came out with quarterly earnings of $1.14 per share, missing the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.22 per share a year ago.
Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Agilent Technologies (A). But which of these two companies is the best option for those looking for undervalued stocks?
Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Abbott (ABT). But which of these two stocks is more attractive to value investors?
Investors looking for stocks in the Medical - Products sector might want to consider either Prestige Consumer Healthcare (PBH) or Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now?
Prestige Consumer Healthcare benefits from e-commerce momentum, acquisitions and solid solvency, even as inflation and tariff costs pose near-term risks.
Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?
Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Abbott (ABT). But which of these two stocks is more attractive to value investors?